

AI Leapfrogging Pharma Industry

A perspective by
Abhay Shukla

Senior Director, Advanced Analytics Solutions
Optum | UnitedHealth Group



AI is no-more an Alien / AI is already in-action



Moderna Therapeutics used ML technologies to expedite mRNA sequencing for COVID-19 treatment:

- By embracing advanced analytics early on, alongside its focus on mRNA-based therapeutics, **Moderna leveraged ML technology to speed up development of Covid vaccine mRNA-1273**
- This was ready to initiate Phase 1 clinical trials in a **record-breaking time 42 days** following COVID-19 sequencing



Sumitomo Dainippon
Pharma

Reduction in preclinical development to less than **12 months from 4 to 5 year**

- A new drug candidate, DSP-1181, created using Exscientia Centaur Chemist **Artificial Intelligence platform**.
- The drug was developed together with Sumitomo Dainippon Pharma for the treatment of obsessive-compulsive disorder.

Increase patient engagement and participation rates using wearable patch

- Sanofi – Mentalab: Mentalab combines a wearable patch that can **measure electrocardiogram bio signals continuously**.
- The patch can be applied by patients directly, and worn throughout their daily activities, while **data is transmitted and analyzed seamlessly**.




AI is transforming All Business

AI Investments:

- A 40% projected growth from 2017 to 2024 indicates that AI will likely revolutionize the pharmaceutical and medical sectors.
- By 2024, AI investments in silico drug discovery will double to fuel growth of genomics and precision medicine to bring vital vaccines and medicines to patients faster.
- Investment in AI for real-world evidence by life sciences companies will double by 2025, driven by health data interoperability initiatives and platforms.
- By 2026, the increased adoption of medication adherence apps, smart IoT-based solutions, and connected drug delivery systems will reduce treatment compliance gaps in clinical trials by one-third

Increasing Proportion of Leaders are Opening Up in Life Science for Adopting AI



Source: AI Strategies Buyer View, IDC, April 2021, N=2000

Pharma is all Ready for AI Enablement

With Goals of
Pharma Industry,
Startups and
Pharma
Partnership is all
geared for rapid AI
transformation


Top Pharma Company Partnerships or Acquisitions within AI Space				
Pharma Company	AI Driven Companies			
	Owkin	GNS Healthcare	Flatiron	Synapse
	Benevolent AI	Winter Light		
	IBM Watson	MIT	Intel	Quantum Black
	IBM Watson	MIT	XtalPS	
	Atomwise	Numerate		
	Berg	Exscientia	Recursion	
	Berg			
	Berg	Exscientia	Cloud Pharmaceuticals	Insillico Medicine
	Atomwise	AiCure		
	Path AI			

Development

Target Discovery

Drug Discovery

AI Role in Pharma Value Chain



discovery

Drug discovery time reduced from 4-5 years to mere 8 months for solid tumors

Examples of AI tools used in drug discovery

- DeepNeuralNetQSAR – for [Detection of the Molecular Activity of Compounds](#)
- PotentialNet - Uses CNNs to [Predict Binding Affinity of ligands](#)
- Hit Dexter - ML technique to [Predict Biochemical Assays](#)
- Neural graph fingerprint - Helps to [Predict Properties of Novel Molecules](#)


- **AI in Drug design**
- **AI in Polypharmacology**
- **AI in Chemical Synthesis**
- **AI in Drug Repurposing**
- **AI in Drug Screening**

AI solutions for drug discovery accounted for about 30% of the total AI and Big Data analytics market for the pharmaceutical industry

AI in Clinical Trial



AI-enabled Clinical Trial Enrichment Strategies



Open-source web tool, called DQueST- filter out 60–80% of trials that the user was not eligible for, with an accuracy of a little more than 60%.



Reduced Population Heterogeneity

- Biomarker verification to reduce variability and increase study power

Prognostic Enrichment

- Selecting patients more likely to have measurable clinical end-points

Predictive Enrichment


- Identifying patients more likely to respond to the treatment

ML and DL methods can be applied to mine, analyze, and interpret multiple data sources, including EHR, medical imaging, and 'Omics' data

More to explore Clinical data using AI

Factors that contribute to health outcomes, %

Social determinants of health
Health behaviors
Clinical Care
Non-modifiable factors (genetics)



Avg. amount of data generated over a person's lifetime

1,100 terabytes (volume, variety, velocity, veracity)

0.4 terabytes (clinical data)

6 terabytes

Exogenous Data

What we don't know

60%

40%

Genomics + Clinical Data

What we could know

Source: Bureau of Labor Statistics; Robert Wood Johnson Foundation; IBM Watson (Latts L. *The age of big data and the power of Watson*. European Medicines Agency presentation. Updated April 1, 2017); McKinsey analysis

Patient Engagement through AI

Chatbots, voice assistants, intelligent search, and intelligent contact center solutions

Analyzing the conversations to provide feedback to clinicians/site coordinators

Remote follow-ups through an intelligent contact center solution

AI-driven patient retention and engagement solution in clinical Trials

Leveraging remote endpoints capture

Mobile apps to capture behavioral, study, and therapeutic data

Develop a patient profile and identify non-compliance, predict dropouts, & adverse events

Products and Solutions

Mabu social robo - Mabu is provided to trial participants so that they can more easily follow their study-related activities and surveys

Mabu platform organizes all aspects of the patient protocol with reminders for medications, appointments, lab visits, telemedicine, and evaluations

Secure, browser-based dashboard allows the trial team to access and coordinate key information in near real time

Pfizer has collaborated Catalia Health for Mabu Wellness Coach

Transform relationship with patients through a SaaS-based platform built to serve both patients and the life sciences industry


IQVIA Orchestrated Patient Engagement (OPE) enables pharmaceutical companies to improve communication and orchestration with the audience that matters most—the patient

IQVIA has partnered with Belong to deliver patient engagement via a configurable, personalized SaaS based solution, Orchestrated Patient Engagement (OPE)

Catalia
Health



IQVIA



AI & ML – Impact on Patient Adherence



Chatbots: Conversational AI focused on medication adherence can build a personalized patient profile and engage them to help stay on track



Smart pills: These pills include ingestible bio-sensors that are embedded into the medicine, which, when consumed, send a signal to the patient and HCP on smart phone; **Example:** FDA approved Abilify MyCite in Nov 2017



Wrist band sensors: The unique motion of taking the drug out of its packaging and consuming it can be tracked



Gamification: Game-based apps aim to instill a behavior change in patients by rewarding them upon continued adherence mainly for chronic diseases



Apps: There are multiple apps currently available on Apple (iOS) and Android OS to aid in improving patient adherence; **Examples** include Groove Health, AiCure, Medisafe, etc.



Smart packaging: There are pill dispensers available in which users can enter dosage and timing for medication and sync the device with the app on their smartphone; **Example:** Fellow Smart Pillbox, CleverCap

Magic Pill

- ✓ **Self Diagnostics:** Imagine a pill which diagnoses and determines the disease on its own
- ✓ **Auto Drug Design:** Drug formulary is designed using AI, based on diagnosis
- ✓ **Auto Dispensing:** Intelligent dispensing the exact amount of drug dosage
- ✓ **One Pill for Multiple Diseases**

Future of AI

What do you think? What's hidden in the Future?



Data Science Reshaping Pharma R&D

Abhay Shukla

Senior Director, Advanced Analytics Solutions

Optum | UnitedHealth Group

